Presentation is loading. Please wait.

Presentation is loading. Please wait.

May 2012 1. 2 Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri Beneficiary 2 : Istituto Superiore di Sanità Beneficiary 3 : Federazione.

Similar presentations


Presentation on theme: "May 2012 1. 2 Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri Beneficiary 2 : Istituto Superiore di Sanità Beneficiary 3 : Federazione."— Presentation transcript:

1 May

2 2 Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri Beneficiary 2 : Istituto Superiore di Sanità Beneficiary 3 : Federazione Nazionale dellIndustria Chimica Beneficiary 4 : Politecnico di Milano, Dipartimento di Elettronica e Informazione Beneficiary 5 : KnowledgeMiner Software Frank Lemke

3 May Promotion of non testingmethods (NTM) fortheiruse in the REACH contextlinking scientists, regulators and industries toevaluate and validateexisting NTM fortheirapplicationaccordingto REACH needs

4 May REACH &I NNOVATION REACH promotes Innovation (Article 1) QSAR ismentioned AllInfo should be used

5 May = f ( )

6 May Survey of current methods for the compliance to the REACH legislation Identification of the criteria for the non-testing methods for the REACH legislation Identification of suitable experimental databases/data sets for the ecotoxicological, toxicological and environmental endpoints for REACH List of (Q)SAR models for the ecotoxicological, toxicological and environmental endpoints for REACH, and their review Validation of non-testing methods (incl. read-across) Identification of boundaries for best use of models (applicability domain) and of the assessment factors

7 May Architecture for integration of different non-testing methods for best performances and coverage of applicability Communication and dissemination initiatives Web portal Project management Monitoring Audit After-LIFE Communication plan

8 May Endpointsproducedfor REACH byLaboratories

9 May Global Predictions on the 1544 compounds (CPDB+Leadscope) of the seven programs examined

10 May BCF – Best Models based on R2 and Accuracy Ordered by R2

11 May

12 May IN SELECTED CASES NON-TESTING METHODS CAN BE USED: BEST MODELS: mutagenicity, BCF; CRITICAL MODELS: daphnia, carcinogenicity; Important to consider the applicability domain; Important the correct evaluation of the results (expert); USE of more than one model preferable.


Download ppt "May 2012 1. 2 Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri Beneficiary 2 : Istituto Superiore di Sanità Beneficiary 3 : Federazione."

Similar presentations


Ads by Google